Page last updated: 2024-11-12

beta-acetyldigoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acetyldigoxins: Alpha- or beta-acetyl derivatives of DIGOXIN or lanatoside C from Digitalis lanata. They are better absorbed and longer acting than digoxin and are used in congestive heart failure. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10350481
CHEBI ID135892
SCHEMBL ID1302063
MeSH IDM0000184

Synonyms (41)

Synonym
kardiamed
16'-acetyldigoxin
cardioreg
digorid b
card-20(22)-enolide, 3-((o-4-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1.4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1.4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-
digotab
cor-puren
acetyl-digoxin-beta
digoxin, 4'''-acetate
einecs 226-337-5
digoxigenin + zuckerkette wie bei acetyl-digitoxin-alpha [german]
4'''-acetyldigoxin
beta-acetyldigoxin
novodigal
digoxin didier
digoxin, acetate, beta-
corotal (tn)
D07556
5355-48-6
acetyldigoxin beta isomer
CHEBI:135892
acetyldigoxins
SCHEMBL1302063
unii-p7k44m64cw
p7k44m64cw ,
digoxigenin + zuckerkette wie bei acetyl-digitoxin-alpha
.beta.-acetyldigoxin [mi]
beta-acetyldigoxin [who-dd]
acetyldigoxin-beta
3.beta.-((4-o-acetyl-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-12.beta.,14-dihydroxy-5.beta.-card-20(22)-enolide
.beta.-acetyldigoxin [ep impurity]
digoxin impurity j [ep impurity]
.beta.-acetyldigoxin
card-20(22)-enolide, 3-((o-4-o-acetyl-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy )-12,14-dihydroxy-, (3.beta.,5.beta.,12.beta.)-
digoxin impurity j
DTXSID30201760
[(2r,3s,4s,6s)-6-[(2r,3s,4s,6s)-6-[(2r,3s,4s,6r)-6-[[(3s,5r,8r,9s,10s,12r,13s,14s,17r)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]ox
Q18030160
C22190
beta-acetyl digoxin
beta -acetyl digoxin

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Coadministration of quinidine sulphate induces a prolongation of digoxin elimination half-life (means +/- SD) from 33."( Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?
Rameis, H, 1985
)
0.27
" Following an open two-compartment model a mean elimination half-life of 60."( On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.
Alken, RG; Becker, U; Haustein, KO; Lach, HJ; Rietbrock, N, 1983
)
0.27
" MRT and tmax were also unchanged, while the elimination rate constant was decreased slightly by 12%, which is of no therapeutic relevance."( The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin.
Degner, FL; Heinzel, G; Narjes, H; Türck, D, 1995
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Trough values during steady state and 24 h AUC were used to calculate digoxin bioavailability for tablets and oral solution."( [Absolute bioavailability of beta-acetyldigoxin from tablets and drops in healthy subjects].
Dammann, HG; Dreyer, M; Endell, W; Iven, H; Rudolph, M, 1992
)
0.57
" In six volunteers the bioavailability of 16AG from two PAG tablet formulations (1."( On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations.
Haustein, KO, 1986
)
0.27

Dosage Studied

There is greater danger of digitalis toxicity in patients with cirrhosis of the liver on standard dosage of beta-methyldigoxin. According to our findings, there is more danger ofDigitalis toxicity on a standard dose of metildigoxin than on astandard dosage of Beta-acetyldigoxin.

ExcerptRelevanceReference
" On the 3rd day of the pengitoxin dosage schedule, a mean plasma level of 18."( Pharmacokinetics of pengitoxin and its therapeutic efficacy in congestive heart failure.
Haustein, KO; Wesser, M, 1988
)
0.27
"To determine whether nifedipine or diltiazem affect digoxin kinetics, glycoside plasma concentrations and renal excretion were measured before and during dosing in 23 patients with cardiac insufficiency achieving steady-state conditions."( Effects of nifedipine and diltiazem on plasma levels and renal excretion of beta-acetyldigoxin.
Kuhlmann, J, 1985
)
0.5
" Since more than half had signs of early renal function impairment, creatinine clearance should be taken into account when determining the dosage of a digoxin preparation especially in elderly patients; alternatively, digitoxin should be prescribed."( [Epidemiology of digitalis medication. Results of the Munich blood-pressure study].
Döring, A; Keil, U; Koenig, W; Mraz, W; Pöppl, SJ; Stieber, J, 1984
)
0.27
" According to our findings there is more danger of digitalis toxicity in patients with cirrhosis of the liver on a standard dosage of metildigoxin than on a standard dosage of beta-acetyldigoxin."( Changes in metildigoxin pharmacokinetics in cirrhosis of the liver: a comparison with beta-acetyldigoxin.
Bonelli, J; Rameis, H; Waginger, H; Woodcock, B, 1984
)
0.68
" There is greater danger of digitalis toxicity in patients with cirrhosis of the liver on standard dosage of beta-methyldigoxin than on standard dosage of beta-acetyldigoxin."( [Pharmacokinetics of beta-methyldigoxin and beta-acetyldigoxin in patients with cirrhosis of the liver (author's transl)].
Bonelli, J; Hruby, K; Rameis, H; Waginger, H, 1981
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cardenolide glycosideAny member of the class of cardenolides with glycosyl residues attached to position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (86)

TimeframeStudies, This Drug (%)All Drugs %
pre-199066 (76.74)18.7374
1990's11 (12.79)18.2507
2000's7 (8.14)29.6817
2010's2 (2.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.55 (24.57)
Research Supply Index4.67 (2.92)
Research Growth Index3.98 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (16.48%)5.53%
Reviews2 (2.20%)6.00%
Case Studies7 (7.69%)4.05%
Observational0 (0.00%)0.25%
Other67 (73.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]